Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06421675 · RECRUITING

Trial details

NCT number: NCT06421675
Sponsor: Ontario Clinical Oncology Group (OCOG)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Multiple Myeloma

Start date: 2025-03-28
Primary completion: 2026-12-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.